PT  - JOURNAL ARTICLE
AU  - JUN HO YI
AU  - SEOK JIN KIM
AU  - JEONG-OK LEE
AU  - GYEONG-WON LEE
AU  - JAE-YONG KWAK
AU  - HYEON-SEOK EOM
AU  - JAE-CHEOL JO
AU  - YOON SEOK CHOI
AU  - SUNG YONG OH
AU  - WON SEOG KIM
TI  - Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis
AID  - 10.21873/anticanres.16120
DP  - 2022 Dec 01
TA  - Anticancer Research
PG  - 6083--6089
VI  - 42
IP  - 12
4099  - http://ar.iiarjournals.org/content/42/12/6083.short
4100  - http://ar.iiarjournals.org/content/42/12/6083.full
SO  - Anticancer Res2022 Dec 01; 42
AB  - Background/Aim: The combination of bendamustine and rituximab (BR) is highly effective in both treatment-naïve and relapsed or refractory mantle cell lymphoma (MCL). Due to the rarity of MCL and limited accessibility of BR, clinical outcome from BR in the routine clinical practice in Korean patients are limited. Patients and Methods: To evaluate the real-world outcomes of BR treatment for MCL in Korea, medical records from 37 patients were retrospectively analyzed. Results: Twenty-five patients received BR as first-line treatment, and ten, eight, and seven patients were classified as low-, intermediate-, and high-risk by MIPI-classification, respectively. With the follow-up duration of 24.3 months, the three-year progression-free survival (PFS) rate was 80.5%±11.8%. PFS significantly differed according to MIPI-classification (p=0.002) and TP53 status (p=0.042). The three-year overall survival (OS) rate was 92.0%±5.4%. In 12 patients who received BR as salvage treatment, the median age was 66. The median PFS was 12.8 months, and the three-year OS rate was 66.8%±16.2%. Conclusion: BR is an effective regimen for both newly-diagnosed and relapsed or refractory MCL patients in Korea, with favorable response rates and outcomes.